PeproMene Bio Announces Oral Presentation at EHA 2026 Highlighting Favorable Safety and Durable Responses with PMB-CT01 (BAFF-R CAR T-Cell Therapy) in B-cell Lymphomas, Including After Prior CD19 CAR T-Cell Failure

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

PeproMene-Bio-@-EHA

More Like This

PR Newswire associated0

PeproMene Bio's PMB-CT01 BAFFR-CAR T Data Selected for Two Oral Presentations at 67th ASH 2025 Annual Meeting

PR Newswire associated0

PeproMene Bio, Inc. Announces Complete Remission of the Cohort 1 First Patient Treated for Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL) in the Phase 1 Clinical Trial of PMB-CT01 (BAFFR-CAR T Cells) at City of Hope

PR Newswire associated0

PeproMene Bio, Inc. and the Institute for Follicular Lymphoma Innovation Announce $11M Investment to Advance PMB-CT01 (BAFF-R CAR T cell therapy) for Relapsed/Refractory Follicular Lymphoma

PR Newswire associated0

PeproMene Bio announced study demonstrating strong polyfunctionality of novel chimeric antigen receptor (CAR) T cells

PR Newswire associated0

PeproMene Bio, Inc. and the Institute for Follicular Lymphoma Innovation (IFLI) Announce The First Follicular Lymphoma (FL) Patient Treated with BAFF-R Targeting CAR-T Cells (PMB-CT01) Achieves a Complete Response

PR Newswire associated0

Biosyngen's first-in-class CAR-T asset targeting solid tumors has entered pivotal phase II trial, Phase I trial data debut at ESMO 2024 Annual Congress

AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026

Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma